July 22, 2020
Chiome Bioscience, a Tokyo-based drug discovery startup, said on July 21 that it has sealed an agreement with the National Cancer Center (NCC) to commence a first-in-human (FIH) trial for its anti-DLK-1 antibody CBA-1205. According to the biotech, there is...read more